Compare Amphastar Pharmaceuticals Inc (AMPH) vs Royal Bank of Canada (RY) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Royal Bank of Canada (RY) trades at $211.09, up 1.21% today, with a bullish technical signal and strong fundamental performance. Recent quarterly earnings consistently beat estimates, with Q1 2026 EPS of $2.84 exceeding the $2.81 forecast. Revenue grew to $66.53B in 2025, and net income margin improved to 31.85%. The company maintains a solid dividend, recently increasing it to $1.76 per share, and announced a share repurchase program.

RY's outlook is positive, supported by earnings momentum and shareholder returns, but faces risks from economic softness and high valuation multiples. Analyst sentiment is mixed, with a majority hold rating, reflecting caution amid rich valuations. The stock's current price near resistance at $211 suggests potential for consolidation before further gains.